

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(21) Application number: 88904653.8

(22) Date of filing: 28.05.88

Data of the international application taken as a basis:

(88) International application number:
PCT/JP88/00525

(87) International publication number:
WO88/09343 (01.12.88 88/26)

(51) Int. Cl.³: **C 07 K 13/00**
C 07 K 15/12, C 12 P 21/02
C 12 N 1/20, C 12 N 15/00
A 61 K 37/02, A 61 K 39/085
/(C12P21/02, C12R1:19)

(30) Priority: 29.05.87 JP 131726/87

(43) Date of publication of application:
31.05.89 Bulletin 89/22

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **SAGAMI CHEMICAL RESEARCH CENTER**
4-5, Marunouchi 1-chome
Chiyoda-ku Tokyo 100(JP)

(71) Applicant: **CENTRAL GLASS COMPANY, LIMITED**
5253, Oaza Okube Ube-shi
Yamaguchi 755(JP)

(71) Applicant: **HODOGAYA CHEMICAL COMPANY, LIMITED**
4-2, Toranomon 1-chome Minato-ku
Tokyo 105(JP)

(71) Applicant: **NIPPON SODA CO., LTD.**
2-1, Ohtemachi 2-chome
Chiyoda-ku Tokyo, 100(JP)

(71) Applicant: **NISSAN CHEMICAL INDUSTRIES, LIMITED**
7-1, Kanda-Nishiki-cho3-chome
Chiyoda-ku Tokyo101(JP)

(71) Applicant: **TOSOH CORPORATION**
4560, Oaza-Tonda Shinnanyo-shi
Yamaguchi 746(JP)

(72) Inventor: **MIKI, Tetsuzo**
2-1 A-908, Shishinden
Abiko-shi Chiba 270-11(JP)

(72) Inventor: **KATO, Seishi**
1-9-2, Minamidai
Sagamihara-shi Kanagawa 228(JP)

(72) Inventor: **OSADA, Hiroshi**
4-19-12, Tsukushino
Machida-shi Tokyo 194(JP)

(74) Representative: **Patentanwälte Grünecker, Dr.**
Kinkeldey, Dr. Stockmair, Dr. Schumann, Jakob, Dr.
Bezold, Meister, Hilgers, Dr. Meyer-Plath
Maximilianstrasse 58
D-8000 München 22(DE)

EP 0 317 641 A1

(54) **FUSED PROTEIN CONTAINING LYMPHOTOXIN.**

(57) This invention relates to a fused protein comprising a polypeptide containing an antibody combining site of protein A and a polypeptide of lymphotoxin and having biological activities derived from lymphotoxin and a capability of combining with an antibody. This invention also provides a process for preparing said fused protein, a DNA coding said fused protein necessary for said process, a plasmid containing said DNA and Escherichia coli transformed with said plasmid.

DESCRIPTION

TITLE OF THE INVENTION

Fused Protein Comprising Lymphotoxin

TECHNICAL FIELD

5 The present invention relates to a fused protein
comprising a polypeptide containing an antibody binding
site of protein A and a polypeptide of lymphotoxin, DNA
coding for the fused protein, plasmids containing the
DNA, Escherichia coli transformed with the plasmid, and
a process for production of the fused protein using the
10 E. coli.

BACKGROUND ART

Recently, studies have been made of targeting
therapy, wherein a monoclonal antibody specific to
cancer cells is linked to a anticancer substance to
15 focus the anticancer substance onto the cancer tissue
using the specificity of the monoclonal antibody.

Although, as anticancer substances used in such an
approach, a plant toxin ricin, diphtheria toxin and the
like have been studied, the use of lymphotoxin as a
20 anticancer substance for the targeting therapy has not
been attempted.

As methods of linking a cancer-specific antibody
and an anticancer substance wherein they are directly
covalently linked, a method wherein a liposome encapsu-
25 lating an anticancer substance is linked to a
cancer-specific antibody, and the like, is known.

Nevertheless, an attempt wherein an affinity of
protein A to an antibody is used to link a cancer-
specific antibody and an anticancer substance for the
30 targeting therapy has not been made.

Although it is already known to prepare a fused
protein comprising protein A and a physiologically
active peptide (WO 84/03103), this approach is mainly
directed to an affinity purification of the physiologi-
35 cally active peptide and the preparation of an antigen

for immunization.

A conventional approach wherein an anticancer substance is chemically linked to a cancer-specific antibody for the targeting therapy is disadvantageous in that it is difficult to make the anticancer substance enter cancer cells. Conversely, it is known that lymphotoxin selectively and directly kills cancer cells via receptors on a surface of the cancer cell. Accordingly, the present invention is intended to provide a means of an effective cancer therapy such as a targeting therapy using lymphotoxin having such an advantageous property.

DISCLOSURE OF THE INVENTION

To attain the above-mentioned object, the present invention provides a fused protein comprising a polypeptide containing an antibody binding site of protein A and a polypeptide of lymphotoxin, and having both a biological activity originally exhibited by the lymphotoxin, i.e., anticancer action, and an ability to bind to the antibody originally exhibited by protein A; as well as a process for production of the fused protein, and DNA coding for the fused protein necessary for that production process, plasmids containing the DNA and E. coli transformed with the plasmid.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the construction of plasmid pLTM1; Fig. 2 shows the construction of plasmid pLTM2; Figs. 3-1 and 3-2 show a nucleotide sequence of DNA coding for a native lymphotoxin in a starting plasmid pLTM2 for the construction of plasmids of the present invention, and an amino acid sequence of a corresponding polypeptide;

Figs. 4-1 and 4-2 show a part relating to the present invention of a nucleotide sequence of DNA coding for protein A in plasmid pRIT2T, and an amino acid sequence of a corresponding polypeptide;

Fig. 5 shows the construction of plasmid pLTM9;

Fig. 6 shows the construction of plasmid pPRALT1 of the present invention; and,

Fig. 7 shows a nucleotide sequence at a junction of the present fused protein and a corresponding amino acid sequence.

BEST MODE OF CARRYING OUT THE INVENTION

Since the present fused protein exhibits an anti-cancer action at the lymphotoxin protein thereof and has an ability to bind to an antibody at the protein A portion thereof due to its affinity therewith, the fused protein can bond to an antibody specific to a cancer, for example, a monoclonal antibody, to form a complex. Therefore, when such a complex is parenterally administered, it is expected to concentrate at cancer cells, where the fused protein is given to the cancer cells by the affinity between lymphotoxin receptors on a surface of the cancer cell and the fused protein.

A. Fused protein and DNA coding therefor

The present fused protein comprises a polypeptide containing an antibody binding site of protein A and a polypeptide of lymphotoxin, and optionally, containing an oligopeptide between these polypeptides.

(1) Polypeptide containing an antibody binding site of protein A and DNA coding therefor

The length of this protein is not critical as long as it possesses an antibody binding ability. An amino acid sequence of protein A has been already determined, and a plasmid containing a DNA coding the protein A is commercially available, and therefore, such a plasmid can be used in the present invention, as a starting plasmid. One of these plasmids, for example, plasmid pRIT2T, is available from Pharmacia (Fig. 5). In a nucleotide sequence coding for an amino acid sequence of protein A in this plasmid, a portion relating to the present invention is shown in Figs. 4-1 and 4-2.

(2) Polypeptide of lymphotoxin and DNA coding therefor

A polypeptide of any length can be used as this portion, as long as it exhibits a biological activity of lymphotoxin in the form of a fused protein. As an embodiment of the present invention, a full length peptide of human lymphotoxin is used.

A series of plasmids pLT1, pLTM1, and pLTM2 containing a cDNA for native lymphotoxin have already been obtained, and the construction processes thereof are described in detail in Japanese Patent Application No. 61-123700. Escherichia coli X 1776/pLT1, which contains the plasmid pLT1, was deposited with the Fermentation Research Institute Agency of Industrial Science and Technology (FRI) as FERM P-8784, and Escherichia coli X 1776/pLTM2, which contains the plasmid pLTM2, was deposited with the FRI as FERM P-8785. The processes for the construction of these plasmids are described hereinafter in Reference Examples, and summarized in Figs. 1 and 2. Accordingly, construction of the plasmids of the present invention can be started from the above-mentioned plasmids. Note, the DNA sequence coding for lymphotoxin in the starting plasmid of the present invention, and a corresponding amino acid sequence, are set forth in Figs. 3-1 and 3-2.

(3) Linker oligonucleotide and DNA sequence coding therefor

In the present invention, an oligonucleotide sequence such as a consensus SD sequence is optionally inserted between a DNA coding for a polypeptide containing an antibody binding site of protein A and a DNA coding for a polypeptide of lymphotoxin, during the construction of an expression plasmid coding for the present fused protein. Therefore, the present fused protein includes, in addition to those wherein a polypeptide containing an antibody binding site of protein A is directly linked to a polypeptide of

lymphotoxin, those wherein they are linked via an oligonucleotide linker encoded by the above-mentioned oligonucleotide.

B. Plasmid

5 The plasmids of the present invention are those containing the above-mentioned DNA coding region under the control of appropriate control sequences, and capable of expressing the DNA code sequence in E. coli. As a promoter, for example, a P_L promoter, tac promoter, 10 trp promoter, lacUV5 promoter or the like can be used, and as an SD sequence, for example, an SD sequence of a metapyrocatechase gene and a consensus SD sequence can be used.

 To enhance the expression of lymphotoxin in E. coli, 15 the present inventors constructed three plasmids, pLTM7, pLTM9, and pLTM11, from a plasmid pLTM2. In the plasmid pLTM7, the 3'-non-translation region of lymphotoxin in the plasmid pLTM2 has been deleted, and therefore, due to a lack of a region present in the deleted 20 region, which destabilizes the mRNA, the expression level can be increased by about two times. The plasmid pLTM9 comprises the plasmid pLTM7 provided with an ideal consensus SD sequence, and due to the improvement of an SD region, the expression level is further increased by 25 about two times. The plasmid pLTM11 is a plasmid wherein codons for leucine and proline following the N-terminal methionine in the plasmid pLTM9 have been improved in a manner which is preferable for the transcription of mRNA, and the expression level is 30 increased by a further about two times.

(1) Construction process for plasmid pLTM7

 A DNA fragment containing the lymphotoxin gene is obtained from the starting plasmid pLTM2 containing a lymphotoxin gene, using EcoRI, and inserted 35 to M13 phage at the EcoRI site, and a specific nucleotide replacement mutagenesis is carried out using an oligonucleotide primer to insert an EcoRI site

downstream of a translation stop codon of the lymphotoxin gene, to thus obtain a mutant phage LTM61.

A double-stranded DNA of the mutant phage is cut with EcoRI to obtain the lymphotoxin gene, which is then inserted to an EcoRI vector fragment of plasmid pLTM2 from which the lymphotoxin gene has been deleted, to obtain a plasmid pLTM7. This process is described in detail in Example 1.

(2) Construction process for plasmid pLTM9

Next, the plasmid pLTM7 is cleaved with a restriction enzyme XcyI to generate a DNA fragment containing the lymphotoxin gene, and the above-mentioned linker is attached to this fragment, and by an additional cleavage with EcoRI, an EcoRI-EcoRI DNA fragment of 537 bp comprising the lymphotoxin gene and the linker nucleotide is obtained. This DNA fragment is inserted to an EcoRI vector of the plasmid pLTM2 from which the lymphotoxin gene has been deleted, to obtain a plasmid pLTM9. The detailed process and sequence of an oligonucleotide used as a linker are set forth in Example 2.

(3) Construction process for plasmid pLTM11

A phage LTM18 and plasmid pLTM11 are obtained from the plasmid pLTM9, by a procedure similar to the construction process for the plasmid pLTM7. This process is described in detail in Example 3.

(4) Construction process for plasmid pPRALT1

The plasmid pLTM9 containing lymphotoxin gene is cut with EcoRI to obtain a DNA fragment containing lymphotoxin gene, which is then inserted to an EcoRI site of a plasmid pRIT2T coding for the above-mentioned protein A to obtain a plasmid pPRALT1 containing a gene coding for a fused protein of the present invention. This process is described in detail in Example 4. Escherichia coli X 1776/pPRALT1, which contain the above-mentioned plasmid pPRALT1, was deposited with the Fermentation Research Institute

Agency of Industrial Science and Technology as FERM
BP-1899 (original national deposition FERM P-9389).

C. E. coli to be transformed

According to the present invention, any strain
5 of E. coli conventionally used for production of a
polypeptide by a gene engineering technique can be used
and, for example, N48301, RR1, RB791, SM32, HB101, N99,
JMI03 and the like are mentioned.

D. Expression of desired polypeptide

10 To express a desired protein, E. coli trans-
formed with the above-mentioned plasmid is cultured in,
for example, an LB medium by a conventional method, and
an induction is applied in accordance with a promoter
used. Next, the produced polypeptide is recovered from
15 the cells of E. coli to obtain the desired polypeptide.
This method is hereinafter described in detail in the
Examples.

E. Cytotoxic activity

Cytotoxic activity of the polypeptide obtained
20 as described above can be measured by, for example, a
microplate method. This measuring method and the
results obtained are described hereinafter in detail in
the Examples.

The present fused protein maintains the
25 cytocidal activity originally exhibited by lymphotoxin.

F. Affinity of fused protein to antibody

As described in detail in the Examples, the
present fused protein has an affinity to an antibody,
and can complex with the antibody.

30 The present invention is now more specifically
described in the Examples.

Example 1. Construction of Plasmid pLTM7

(1) Introduction of EcoRI site to a position
immediately downstream of a stop codon

35 The plasmid pLTM2 was cleaved with the
restriction enzyme EcoRI, and a fragment containing a
lymphotoxin gene was recovered from 0.8% agarose.

Then, 0.5 pmole of this DNA fragment was mixed with 0.5 pmole of double-stranded DNA of phage M13mp10 which had been cleaved with EcoRI, and the mixture was ligated in 20 μ l of a solution containing 66 mM Tris-HCl (pH 7.5), 5 mM $MgCl_2$, 5 mM DTT and 1 mM ATP using 100 units of T4 DNA ligase at 12°C for 16 hours. After the reaction, the reaction mixture was used to transform E. coli JM103 by a procedure of Messing et al., Methods in Enzymology, 101, 20-78, 1983, and the mixture was plated with soft agar containing 0.02% X-gal and 1 mM IPTG, and cultured at 37°C overnight. A single stranded template DNA was prepared from a white plaque formed by transformant. Namely, the white plaque was picked up with a toothpick, and suspended in 1.5 ml of 2XYT culture medium (1.6% Bacto trypton, 1% yeast extract and 0.5% NaCl) in which E. coli JM103 was growing, and culturing was carried out at 37°C for five hours. A single-stranded recombinant phage DNA was recovered from the supernatant by polyethyleneglycol precipitation, phenol treatment, and ethanol precipitation.

The single-stranded DNA thus obtained was used as a template to determine a nucleotide sequence, by a dideoxy method of Messing et al., (supra) to confirm a sequence of the cloned single-stranded DNA. In this manner, a single-stranded DNA comprising an anti-coding strand of lymphotoxin gene was obtained, and this recombinant phage was designated as LTM21.

A single-stranded DNA of LTM21 thus obtained was used as a template, and a synthetic oligonucleotide:

CGC TCT GTA GAA TTC GGA AAA ATC CAG

was used as a primer, to carry out a repair reaction using a Klenow fragment of DNA polymerase. Namely, 2 pmoles of the primer phosphorylated at the 5'-terminal thereof were added to 0.5 pmole of the single-stranded template DNA, and were maintained in 10 μ l of a solution containing 7 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 20 mM NaCl and 7 mM $MgCl_2$ at 60°C for 20 minutes, and then at

23°C for 20 minutes. Next, dATP, dGTP, dTTP and dCTP were added to this mixture to a final concentration of 5 mM to make a total volume of 20 μ l, 2 units of DNA polymerase were added thereto, and incubation was
5 carried out at 23°C for 20 minutes. Next, 1 μ l of 10 mM ATP and one unit of T4 DNA ligase were added, and incubation was carried out overnight at 12°C.

The thus obtained 0.1 pmole of a double-stranded DNA was used to transform E. coli JM103 by the
10 Messings method.

The phage plaques thus obtained were screened for mutant phage by plaque hybridization using the above-mentioned oligonucleotide (phosphorylated with 32 P) as a probe. Namely, the plaques were transferred
15 from the soft agar medium to a nitrocellulose filter, by a Benton - Davis method (W.D. Benton and R.W. Davis, Science, 196, 180, 1977), and the filter was baked in vacuum at 80°C for two hours. This nitrocellulose was subjected overnight to hybridization in 6X SSC, 10X
20 Denhardt solution using the primer oligonucleotide labeled with 32 P as a probe at 23°C. Next, this filter was washed in 6X SSC at 59°C, and autoradiographed to isolate a mutant phage plaque exhibiting a positive signal.

25 A double-stranded phage was prepared by a rapid isolation method from this phage plaque and cleaved with EcoRI to obtain a 715 bp fragment, which was then used as a template for a determination of a nucleotide sequence by the dideoxy method, to confirm
30 that a nucleotide replacement mutation had occurred and a phage having a EcoRI site immediately downstream of the stop codon of lymphotoxin gene was obtained. This mutant phage was designated as JM103/LTM61.

(2) Construction of plasmid and transformation

35 A double-stranded DNA was prepared from the phag JM103/LTM61 by a conventional procedure, and cleaved with a restriction enzyme EcoRI, and a DNA

fragment containing a lymphotoxin gene was recovered by 0.8% agarose gel electrophoresis and purified by Elutip-d. Then 0.5 pmole of the above-mentioned DNA fragment was ligated with 0.5 pmole of an EcoRI fragment not containing a lymphotoxin gene of a plasmid pLTM2 in 40 mM HEPES (pH 7.8), 10 mM MgCl₂, 10 mM DTT, 0.4 mM ATP, using 100 units of T4 ligase, at 12°C for 16 hours.

Subsequently, 10 µl of this reaction mixture was used to transform *E. coli* RR1, and a transformant resistant to 100 µg/ml ampicillin was selected. Plasmid DNA was extracted from a colony of the transformant, and the nucleotide sequence thereof was confirmed by the dideoxy method. This plasmid was designated as pLTM7.

Example 2. Construction of plasmid pLTM9 (Fig. 5)

First, 24 µg of the plasmid pLTM7 (156 µl) was incubated with 60 units of restriction enzyme XcyI (24 µl) and 20 µl of XcyI buffer at 37°C for four hours, and then 9 µg (20 µl) each of 5'-phosphorylated oligonucleotides #96 and #97:

AATTCAAAGGAGGTTTAAATATGCTC	#96
GTTCCTCCAAATTTATACGAGGGCC	#97
<hr/>	
EcoRI Aha III XcyI	

were added to the reaction mixture, the mixture was extracted with phenol and chloroform, and DNA was precipitated with ethanol and dried. This DNA was reacted in 40 mM HEPES (pH 7.8), 10 mM MgCl₂, 10 mM DTT and 0.4 mM ATP, using 100 units of T4 ligase, at 12°C for 16 hours. The reaction mixture was then extracted with phenol and chloroform, and subsequently, DNA was precipitated with ethanol and dried.

This precipitate was dissolved in 160 µl of distilled water, the solution was mixed with 300 units of EcoRI (20 µl) and 20 µl of an EcoRI buffer, the mixture was incubated at 37°C for two hours, and then frozen.

This reaction mixture was separated by electrophoresis using 2% agarose gel, and a gel section containing a 537 bp DNA fraction was cut out and subjected to an electrodialysis in a dialysis membrane.

5 The extract was applied to an Elutip-d column, and after the DNA was adsorbed, the column was washed, and by increasing an ion concentration in an eluent, the DNA was eluted and recovered. The DNA was precipitated with ethanol, and the precipitated DNA was dried and

10 dissolved in 20 μ l of distilled water.

Then 0.5 pmole of EcoRI fragment not containing a lymphotoxin gene of plasmid pLTM2 was ligated with 0.5 pmole of the above-mentioned DNA fragment in 40 mM HEPES (pH 7.8), 10 mM $MgCl_2$, 10 mM DTT, 0.4 mM ATP,

15 using 100 units of T4 ligase, at 12°C for 16 hours.

Then 10 μ l of this reaction mixture was used to transform E. coli RR1, and a transformant resistant to 100 μ g/ml ampicillin was selected. Plasmid DNA was extracted from a colony of the transformant, and the

20 nucleotide sequence thereof was confirmed by the dideoxy method. This plasmid was designated as pLTM9.

Example 3. Construction of plasmid pLTM11

The plasmid pLTM9 having modified codons for the second leucine and the third proline was cleaved with restriction enzyme EcoRI, and a fragment containing the lymphotoxin gene was recovered from 0.8% agarose gel.

25

Then 0.5 pmole of this DNA fragment was mixed with 0.5 pmole of a double-stranded DNA of phage M13 mp10 which has been cleaved with EcoRI, and ligation was

30 carried out in 20 μ l of a solution containing 66 mM Tris-HCl (pH 7.5), 5 mM $MgCl_2$, 5 mM DTT and 1 mM ATP, using 100 units of T4 DNA ligase, at 12°C for 16 hours. After the reaction, the reaction mixture was used to transform E. coli JM103 by the Messing et al., Method in

35 Enzymology, 101, 20-78, 1983, and the mixture was plated with soft agar containing 0.02% X-gal and 1 mM IPTG, and culturing was carried out overnight at 37°C. From a

white plaque formed by a transformant, a single-strand d
DNA was prepared. Namely, a white plaque was picked up
with a toothpick, suspended in 1.5 ml of 2X YT medium
(1.6% Bacto trypton, 1% yeast extract and 0.5% NaCl) in
5 which E. coli JM103 was growing, and culturing was
carried out at 37°C for five hours to obtain a culture
supernatant from which a single-stranded recombinant
phage DNA was recovered by polyethyleneglycol precipita-
tion, phenol treatment, and ethanol precipitation.

10 The nucleotide sequence of the single-stranded DNA
thus obtained was determined by the dideoxy method of
Messing et al., supra, and a sequence of cloned single-
stranded DNA was confirmed. In this way, a single-
stranded DNA containing an anti-coding strand of the
15 lymphotoxin gene was obtained. This recombinant phage
was designated as LTM71.

A single-stranded DNA of the LTM71 thus obtained
was used as a template with a synthetic oligonucleotide:

T TTA AAT ATG TTA CCT GGT GTT GG

20 as a primer to carry out a repair reaction using a
Klenow fragment of DNA polymerase. Namely, 2 pmoles of
the primer phosphorylated at the 5'-terminal thereof
were added to 0.5 pmole of the single-stranded template
DNA, and were maintained in 10 µl of a solution
25 containing 7 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 20 mM
NaCl and 7 mM MgCl₂ at 60°C for 20 minutes, and then at
23°C for 20 minutes. Next, dATP, dGTP, dTTP and dCTP
were added to this mixture to a final concentration of
5 mM to make a total volume of 20 µl, 2 units of DNA
30 polymeran were added thereto, and incubation was carried
out at 23°C for 20 minutes. Next, 1 µl of 10 mM ATP and
one unit of T4 DNA were added, and incubation was
carried out overnight at 12°C.

Then 0.1 pmole of a double-stranded DNA thus
35 obtained was used to transform E. coli JM103 by the
Messing method.

The phage plaques thus obtained were screen d for

mutant phage by plaque hybridization using the above-mentioned oligonucleotide (phosphorylated with ^{32}P) as a probe. Namely, the plaques were transferred from the soft agar medium to a nitrocellulose filter by a Benton
5 - Davis method (W.D. Benton and R.W. Davis, Science, 196, 180, 1977), and the filter was baked in a vacuum at 80°C for two hours. This nitrocellulose was subjected overnight to hybridization in a 6X SSC, 10X Denhardt solution using the primer oligonucleotide labeled with
10 ^{32}P as a probe at 23°C. Next, this filter was washed in 6X SSC at 59°C, and autoradiographed to isolate a mutant phage plaque exhibiting a positive signal.

A double-stranded phage was prepared from this phage plaque, by a rapid isolation method, and cleaved
15 with EcoRI to obtain a 537 bp fragment, which was then used as a template for a determination of the nucleotide sequence in the dideoxy method to confirm that a nucleotide replacement mutation had occurred and codons for the second leucine and the third proline of the
20 lymphotoxin gene were modified. This mutant phage was designated as JM103/LTM81.

A double-stranded DNA was prepared from the phage JM103/LTM81 by a conventional procedure, and cleaved with a restriction enzyme EcoRI, and a DNA fragment
25 containing a lymphotoxin gene was recovered by 0.8% agarose gel electrophoresis and purified by Elutip-d.

Then 0.5 pmole of the above-mentioned DNA fragment was ligated with 0.5 pmole of an EcoRI fragment not containing a lymphotoxin gene of plasmid pLTM2 in 40 mM
30 HEPES (pH 7.8), 10 mM MgCl_2 , 10 mM DTT, 0.4 mM ATP, using 100 units of T4 ligase, at 12°C for 16 hours.

Subsequently, 10 μl of this reaction mixture was used to transform E. coli RR1, and a transformant resistant to 100 $\mu\text{g/ml}$ ampicillin was selected. A
35 plasmid DNA was extracted from a colony of the transformant, and the nucleotide sequence thereof was confirmed by the dideoxy method. This plasmid was

designated as pLTM11.

Example 4. Construction of plasmid pPRALT1
(Fig. 6)

First, 5 µg of plasmid pRIT2T (obtained from
5 Pharmacia (1 µl) was digested with 15 units of EcoRI
(1 µl) at 37°C for 5 hours, 40 µl of 20 mM Tris-HCl
(pH 8.0) and 10 µl of alkaline phosphatase (E. coli C75)
(1/10 dilution) were added to the reaction mixture, and
the reaction was carried out at 65°C for 40 minutes.

10 The reaction mixture was extracted with phenol and
chloroform, and DNA was recovered by ethanol precipita-
tion, and dried.

Then 0.5 pmole of the DNA precipitate and 0.5 pmole
of EcoRI fragment of the plasmid pLTM9 containing
15 lymphotoxin gene were reacted in 40 mM HEPES (pH 7.8),
10 mM MgCl₂, 10 mM DTT and 0.4 mM ATP, using 100 units
of T4 ligase, at 12°C for 16 hours.

Subsequently, 10 µl of this reaction mixture was
used to transform E. coli RR1, and a transformant
20 resistant to 100 µg/ml ampicillin was selected. Then
plasmid DNA was extracted from a colony of the trans-
formant, and the nucleotide sequence thereof was
confirmed by the dideoxy method. This plasmid was
designated as pPRALT1.

25 Example 5. Confirmation of expression product by
in vitro translation

Expression products obtained by in vitro transla-
tion of the present plasmid pPRALT1 coding for a fused
protein comprising lymphotoxin and protein A and of
30 plasmid pRIT2T coding for protein A were tested using a
DNA expression kit (Amersham). The expression product
was separated by SDS-PAGE using 10%-26% gradient, and
apparent molecular weight was obtained by comparing the
position of a band of the expression product and the
35 position of bands of molecular weight standards. As a
result, it was found that an expression product of
pPRALT1 had a molecular weight of about 48K, and an

expression product of pPIT2T had a molecular weight of about 30K, and therefore, it was confirmed that the plasmid pPRALT1 expressed a fused protein of the present invention.

5 Example 6. Expression of polypeptide and purification

E. coli HB101 containing the above-mentioned plasmid pPRALT1 was incubated overnight in 30 ml of LB medium at 37°C, inoculated to 3 l of LB medium, and the
10 culturing was carried out in a jar fermenter (Iwashiyu) at 37°C for 7 hours. After the culturing, the culture broth was centrifuged to collect microbial cells. The collected cells were thoroughly suspended in phosphate buffer (10 mM sodium phosphate, pH 7.2, 1 mM EDTA), and
15 the suspension was passed three times through a Gaulin Homogenizer at 8000 psi to disrupt the cells. The disruptant was centrifuged at 10,000 rpm for 30 minutes to obtain a supernatant.

 To this supernatant was added ammonium sulfate to
20 5% (w/v) to carry out ammonium sulfate precipitation, and a resulting supernatant was purified by a butyl Toyopearl column (Toso). Namely, 20 ml of the supernatant was applied to 20 ml of butyl Toyopearl 650 M which has been equilibrated with phosphate buffer
25 (10 mM sodium phosphate, pH 7.2, 0.02% Tween 20) containing 5% (w/v) ammonium sulfate, and the column was immediately washed with 100 ml of the same buffer as used for equilibrating the column, and protein adsorbed to the column was eluted with phosphate buffer not
30 containing ammonium phosphate. The eluted fraction contained the desired polypeptide.

Example 7. Confirmation of antibody binding ability of desired polypeptide

 It was confirmed that the desired polypeptide binds
35 to an antibody and that the binding relied on the affinity of the protein A portion. Namely, the desired polypeptide obtained in Example 6 was subjected to

SDS-PAGE, and transferred to a nitrocellulose membrane using a electroblotting apparatus (Biometra). After blocking the membrane with phosphate buffer containing 1% BSA, the membrane was treated with a peroxidase-labeled bovine anti-rabbit IgG (Bethyl Laboratory), and after washing 4-chloro-1-naphthol solution and an aqueous hydrogen peroxide were used to develop a color. As a result, a band of a dark violet was found at a position corresponding to a molecular weight of 44,000. The desired polypeptide bound to a peroxidase-labeled bovine antibody.

Cell extracts (supernatants) obtained from E. coli N48301 containing plasmid pPRALT1 and E. coli RR1 containing plasmid pLTM7 according to a procedure of Example 2 were diluted with phosphate buffer to 1×10^4 U/ml, and a culture supernatant from HUT-102 cells was diluted with phosphate buffer to 1×10^3 U/ml. To 300 μ l of the solution was added 10 μ l of a column carrier, IgG Sepharose 6 fast flow (Pharmacia), and the whole was gently shaken at a room temperature for one hours. The mixture was centrifuged at 6000 rpm to obtain a supernatant A, and the precipitated carrier was washed three times with 200 μ l each of phosphate buffer. After the carrier was separated from the washing solution by centrifugation at 6000 rpm, 300 μ l of phosphate buffer containing 1 mg/ml protein A (Sigma) was added to the carrier, and the whole was gently shaken at a room temperature for one hour. The mixture was centrifuged at 6000 rpm to obtain a supernatant B.

Lymphotoxin activity of the supernatants A and B thus obtained was measured by the above-mentioned procedures, and the following result was obtained.

Plasmid/E. coli	Super-natant A	Super-natant B
pPRALT1/N48301	1×10^2	6×10^2
pLTM7/RR1	1×10^3	2
HUT-102 Supernatant	1×10^2	0
Distilled water	0	0

From the above-mentioned result, it was found that a product from E. coli containing the present plasmid pPRALT1, i.e., the supernatant B from an extract containing a fused protein comprising lymphotoxin and protein A exhibits lymphotoxin activity. This means that the fused protein was adsorbed to the carrier via an antibody (IgG) immobilized to the carrier, and then eluted by exchange with the added protein A.

Accordingly, it was proved by this experiment that the present polypeptide which is a fused protein comprising protein A and lymphotoxin can form a complex with an antibody.

Example 8. Cytocidal activity

Cytocidal activity of the desired polypeptide was measured by a method of B.B. Aggarwal, J. Biological Chemistry, 260, 2345 - 2354. Mouse L-M cells were cultured in Eagle's MEM containing 5% fetal calf serum, 0.5% penicillin, 0.5% streptomycin and 1 μ g/ml actinomycin D, and 3×10^4 cells/100 μ l were put into a well of a plate in which 100 μ l of the above-mentioned diluted sample was added, and culturing was carried out at 37°C under an atmosphere of 5% CO₂ for 24 hours. After washing the plate, to which 100 μ l of a formalin-ethanol solution containing 0.05% crystal violet was added to stain cells for 30 minutes. Next, the dyestuff was eluted with 100 μ l of 0.05M NaH₂PO₄ in ethanol, and absorbance at 570 nm was measured using a photometer

(Minireader II, Dynatech).

The absorbance (normal scale) and dilution ratio (logarithmic scale) were plotted on a semilogarithmic coordinates, and the cytotoxic activity in a sample, expressed in unit, was calculated defining an activity necessary to kill 50% of cells as one unit. The value of the cytotoxic activity was corrected using TNF (Gene zyme) as an internal standard.

A cytotoxic activity of the desired polypeptide obtained in Example 6 was 8.8×10^5 units per 1 mg protein. Accordingly, the present fused protein expressed by plasmid pPRALT1 has lymphotoxin activity.

Reference Example 1.

Preparation and screening of cDNA

(1) Preparation of mRNA

Human T lymphatic leukemia cell line HUT-102 was suspended in 20 ml of RPMI-1640 medium containing 5% fetal calf serum, and cultured in a 5% CO₂ incubator at 37°C for two to three days. A volume of the medium was then increased two-fold every two or three days during the culture, to finally obtain 1 l of the culture broth. The culture broth thus obtained was centrifuged at 4°C and 3000 rpm for 10 minutes to collect the cells which were then suspended in 50 ml of a phosphate buffer (10 mM sodium phosphate, pH 7.2, 0.15 M NaCl) to wash the cells, and the suspension was centrifuged to obtain a pellet of T cells.

mRNA was prepared using the guanidinium/CsCl method of Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, p. 196, 1982. Namely, the T cell pellet was suspended in five volumes of guanidinium isothiocyanate solution (6M guanidinium isothiocyanate, 5 mM sodium citrate, pH 7.0, 0.1 M β -mercaptoethanol and 5% sarcosine), and the suspension was put into a glass homogenizer and homogenized ten times with a Teflon bar. The homogenate was carefully overlaid on 1.5 ml of solution (pH 7.5) containing 5.7M CsCl and 0.1M EDTA in

a centrifuge tube (Ultra C1 an, trade mark) for SW55 roter, and ultra centrifugation was carried out at 15°C and 35,000 for 20 hours. Guanidium solution was removed, a wall of the tube was three times washed with the guanidium solution, the wall of the tube was cut at a level over a surface of CsCl solution. After the CsCl solution was removed, the precipitate was washed two times with 80% ethanol, and dissolved in 500 μ l of a buffer containing 10 mM Tris-HCl (pH 7.4), 5 mM EDTA and 10% SDD (TES). The solution was extracted with 500 μ l of chloroform/n-buthanol (4:1) mixture, and after an organic layer was extracted again with 500 μ l of TES, aqueous layers were combined, and ethanol precipitation was carried out to obtain mRNA.

The mRNA was passed through an oligo (dT) cellulose column by a procedure described in Molecular Cloning, to purify poly (A)⁺ RNA.

(2) Synthesis of cDNA

First, a strand of a cDNA was synthesized by a Gubler-Hoffman method. Namely, 8.4 μ l of water, 1 μ l of 1M Tris-HCl (pH 8.3) (50 mM), 1 μ l of 0.6M KCl (30 mM), 1 μ l of 0.16M MgCl₂ (8 mM), 1 μ l of 20 mM DTT (1 mM), 1.6 μ l of 25 mM dNTP (mixture of 25 mM each dATP, dCTP, dGTP and dTTP) (each 2 mM), 1 μ l of RNasin (Biotech 30 V/ μ l), 2 μ l of oligo (dT) 12-18 (PL) (2 μ l), and 3 μ l of HUT-102 poly(A)⁺ RNA (1 μ g/ μ l) were mixed to make a total volume of 19 μ l, and after preincubation of 37°C for 5 minutes, 1 μ l of reverse transcriptase (Life Science, 12.5 V/ μ l) was added to the mixture, and reaction was carried out at 37°C for one hour. Note, the values in parentheses represent final concentrations of the salts in the solution. After the reaction was terminated by addition of 1 μ l of 0.5M EDTA and 0.5 μ l of 10% SDS, phenol/chloroform extraction, ammonium acetate/ethanol precipitation two times, and washing of the precipitate with 80% ethanol were carried out. the precipitate was dried under a reduced pressure, and

dissolved in 50 μ l of water. To 5 μ l of the solution was added 1 μ g of RNase, and the mixture was allowed to stand at a room temperature for 10 minutes and extracted with phenol. A resulting aqueous layer was subjected to
5 0.7% agarose gel electrophoresis to test an extent of elongation of the first strand.

A second strand was also synthesized according to a condition for synthesis of a second strand in the above-mentioned Gubler-Hoffman method. Namely, 45 μ l of
10 the cDNA first strand solution, 33.5 μ l of water, 2 μ l of 1M Tris-HCl (pH 7.5) (20 mM), 1 μ l of 0.5M $MgCl_2$ (5 mM), 1 μ l of 1M $(NH_4)_2SO_4$ (10 mM), 10 μ l of 1M KCl (100 mM), 1 μ l of 10 mM β -NAD (0.1 mM), 1 μ l of 5 mg/ml BSA (50 μ g/ml), 1 μ l of 4 mM NTP (40 μ M), 1 μ l of E.
15 coli DNA ligase (PL, 0.5 μ g/ μ l), 2 μ l of E. coli DNA polymerase I (PL, 15 V/ μ l), 0.5 μ l of E. coli RNase H (Takara Shuzo, 1.3 V/ μ l) and 1 μ l of ^{32}P -dCTP (10 μ l) were mixed to make a total volume of 100 μ l, and a reaction was carried out at 12°C for one hour, and then
20 at 22°C for one hour. Before and after the reaction, 1 μ l each of a sample was taken and an amount of incorporation of radioactivity was measured by TCA precipitation. After the reaction was terminated by an addition of 4 μ l of 0.5M EDTA and 5 μ l of 10% SDS to the
25 reaction mixture, phenol/chloroform extraction, ethanol precipitation two times, and washing of the precipitate with 80% ethanol were carried out, and the precipitate was dried under a reduced pressure and dissolved in 10 μ l of water.

30 (3) Preparation of cDNA library

Then 10 μ l of cDNA aqueous solution, 2 μ l of water, 0.7 μ l of 1M Tris-acetate (pH 7.9) (35 mM), 1.3 μ l of 1M potassium acetate (65 mM), 2 μ l of 0.1M Magnesium acetate (10 mM), 1 μ l of 10 mM DTT (1 mM) 1 μ l
35 of 5 mg/ml BSA (250 μ g/ml), 1 μ l of 2 mM dNTP (0.1 mM) and 1 μ l of T4 DNA polymrase (Takara Shuzo, 1.5 V/ μ l) were mixed to make a total volume 20 μ l, and reacted

with 37°C for 10 minutes. After the reaction was terminated by an addition of 1 μ l of 0.5M EDTA and 0.5 μ l of 10% SDS, phenol/chloroform extraction, ethanol precipitation two times, and washing the precipitate with 80% ethanol were carried out, and the precipitate was dried under a reduced pressure and dissolved in 10 μ l of water.

To 2 μ l of EcoRI linker (Takara Shuzo; GGAATTCC; 1 μ g/ μ l), were added 5 μ l of water, 2 μ l of 5X linker kinase buffer (0.33M Tris-HCl, pH 7.6, 5 mM ATP, 5 mM spermidine, 50 mM MgCl₂, 75 mM DTT, 1 mg/ml BSA) and 1 μ l of T4 DNA kinase (Takara Shuzo; 6 V/ μ l) to make a total volume of 10 μ l, and a reaction was carried out at 37°C for one hour. To this reaction mixture were added 5 μ l of a solution of cDNA previously blunt-ended as described above, 2 μ l of 5X linker kinase buffer, 1.5 μ l of water, 1 μ l of T4 DNA ligase (Takara Shuzo; 175 V/ μ l), and 0.5 μ l of T4 RNA ligase (PL; 0.8 μ g/ μ l) to make a total volume of 20 μ l, and a reaction was carried out at 12°C overnight or at 22°C for 6 hours. The reaction mixture was heated at 65°C for 10 minutes to inactivate the ligases, and to the reaction mixture were added 65 μ l of water, 10 μ l of 10X EcoRI buffer and 5 μ l of EcoRI (Takara Shuzo; 7.5 V/ μ l) to make a total volume of 100 μ l. The reaction was carried out at 37°C for 3 hours. One tenth volume each of samples were taken before and after the digestion with EcoRI, and subjected to 10% polyacrylamide gel electrophoresis to check whether the EcoRI linker was attached and whether the EcoRI site was cleaved. The reaction mixture was extracted with phenol, and after 5M NaCl was added to a resulting aqueous phase to a final concentration of 0.3M NaCl, the mixture was applied to a Sepharose CL-4B column (2 ml) to eliminate the EcoRI linker. The column was developed with TE (pH 7.6) and 0.3M NaCl, and 4 to 5 drops of fraction of the elute were obtained. Fractions exhibiting radioactivity were then subjected to ethanol

precipitation, and each precipitated fraction was dissolved in 10 μ l of water.

A plasmid pUC9 was cleaved with EcoRI by a conventional procedure and treated with calf intestine alkaline phosphatase (CIP), mixed with 1 μ l of the preparation (0.4 μ g), 10 μ l of the cDNA prepared as above, 20 μ l of 5X linker kinase buffer and 64 μ l of water, and the mixture heated at 68°C for 10 minutes. To the mixture was added 5 μ l of T4 DNA ligase to make a total volume of 100 μ l, and the reaction was carried out at 12°C overnight. The reaction mixture was heated at 65°C for 10 minutes, and 10 μ l of the reaction mixture was mixed with 210 μ l of suspension of E. coli X 1776 competent cells to transform the cells. The transformed cell suspension thus prepared was added to 300 ml of X 1776 medium containing 50 μ g/ml ampicillin, and cultured overnight at 37°C. A portion of the culture in the form of a 15% glycerine suspension was frozen at -80°C and stored.

(4) Screening of cDNA library

First, 20 μ l of the frozen glycerine storing suspension of the cDNA-containing transformants was diluted 5,000-fold with X 1776 medium and 100 μ l of the diluted suspension was spread on a nitrocellulose sheet placed on an X 1776 agar plate containing ampicillin, and cultured overnight at 37°C. Colonies developed on the nitrocellulose sheet were replicated to two nitrocellulose sheets, and these replicas were cultured on X 1776 medium for three hours. The sheets were transferred onto the medium containing 10 μ g/ml chlorophenical, followed by culturing overnight. The filter was subsequently put on 10% SDS, a denaturation solution (0.5N NaOH, 1.5M NaCl), and on a neutralizing solution (1.5M NaCl, 0.5M Tris-HCl, pH 8.0) each for 5 minutes. The sheet was reacted in 5 μ l of a proteinase K solution (1 mg/ml proteinase K (Merk), 0.5M NaCl, 10 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% SDS) at 37°C for one hour, put

between filter papers, strongly rubbed with a roller, twice washed with 2X SSC, and heated at 80°C for three hours.

The above-mentioned nitrocellulose sheet was hybridized overnight with oligonucleotide probe #71 labeled with ^{32}P in 6X SSC, 10X Denhardt solution at 42°C. Next, the sheet was washed at 55°C in 6X SSC, subjected to autoradiography for two days, and as a result, three colonies exhibited positive signals.

Next, this nitrocellulose sheet was washed in 1X SSC solutions at 65°C for 30 minutes, to wash the positive signal away, dried, and again subjected to hybridization with the oligonucleotide probe #72. The hybridization was carried out overnight in 6X SSC, 10X Denhardt solution with the oligonucleotide probe #72 labeled with ^{32}P at 42°C. Next, this sheet was washed in 6X SSC at 50°C, and subjected to autoradiography for two days, and as a result, the same three colonies as those which exhibited a positive signal with the probe #71 again exhibited a positive signal.

Plasmid DNA was extracted from each of these three colonies, and the nucleotide sequence thereof was determined by a conventional procedure. As a result, one of these clones contained a coding sequence for an entire lymphotoxin peptide. This plasmid was designated as pLT1 (Fig. 1).

Reference Example 2.

Construction of plasmid pLMT1 (Fig. 1)

The above-mentioned plasmid pLMT1 was used to transform E. coli RR1, the transformant was cultured, and plasmid DNA was extracted from the cultured cells.

Then 40 μl (20 μg) of pLT1 plasmid DNA, 20 μl of EcoRI buffer (X10), 140 μl of distilled water and 4 μl of EcoRI enzyme solution (40 units) were mixed, and reacted at 37°C for three hours. This reaction mixture was extracted with 100 μl each of phenol and chloroform, washed with 200 μl of ether, and the DNA was

precipitated with ethanol. After drying, the precipitate was dissolved in 100 μ l of an electrophoresis dye solution, and separated by electrophoresis with 1.2% agarose gel in 1X TBE (Tris-Borate-EDTA buffer), and a gel piece containing a desired DNA of about 0.9 kb was cut off. This gel piece was put into a dialysis tube, and subjected to electroelution in 1X TBE for two hours. The solution in the dialysis tube was recovered and applied on an Elutip-d column to adsorb the DNA on the column, which was then washed, and the DNA was eluted, by increasing an ion concentration of an eluent, and recovered. After ethanol precipitation, the precipitate was dried for three minutes, and the DNA thus obtained was dissolved in 20 μ l of distilled water.

Subsequently, 10 μ l of plasmid pKK223-3-containing solution, 5 μ l of EcoRI buffer (X10), 36 μ l of distilled water and 3 μ l of EcoRI (30 units) were mixed, and reacted with 37°C for three hours. Next, to this reaction mixture were added 50 μ l of 50 mM Tris-HCl (pH 8.0) and 10 μ l of bacterial alkaline phosphatase (BAP) C-75 solution (1/10 dilution), and a reaction was carried out at 65°C for one hour. The reaction mixture was extracted with 100 μ l each of phenol and chloroform, washed with 200 μ l of ether and ethanol-precipitated, and the precipitate was dried for three minutes and dissolved in 20 μ l of distilled water.

5 μ l of the above-mentioned pKK223-3 digest, 5 μ l of the above-mentioned pLT1 digest, 10 μ l of 100 mM HEPES (pH 7.8), 10 μ l of 30 mM $MgCl_2$, 1 μ l of 300 mM DTT, 1 μ l of 10 mM ATP and 2 μ l of T4 DNA ligase solution (20 units) were mixed, and reacted overnight at 12°C.

Then, 10 μ l of this reaction mixture and 200 μ l of a suspension of E. coli JM103 competent cells were mixed, and the mixture was spread on an H plate, and culturing was carried out overnight at 37°C. Among the

many colonies formed, 12 colonies were analyzed by a rapid isolation method, and it was confirmed that three colonies contained a desired plasmid. This plasmid was designated as pLTM1.

5 Reference Example 3.

Construction of plasmid pLTM2 (Fig. 2)

 First, 100 μ l (10 μ g) of plasmid pLTM1 solution, 40 μ l of Pvu II buffer (X10), 260 μ l of distilled water and 4 μ l of Pvu II enzyme buffer (40 units) were mixed, and reacted at 37°C for one day. To this reaction mixture were added 360 μ l of distilled water, 40 μ l of Pvu I buffer and 4 μ l of Pvu I enzyme solution (40 units), and a reaction was carried out for one day at 37°C. The reaction mixture was extracted with 400 μ l each of phenol and chloroform, washed with 800 μ l ether, and ethanol-precipitated. The precipitate was dried, and dissolved in 100 μ l of a dye solution for agarose gel electrophoresis, and subjected to electrophoresis with 1.2% agarose gel in 1X TBE. Gel piece containing DNA having lengths of about 1.6 kb and 1.7 kb was cut off. This gel piece was put into a dialysis tube, and electroelution was carried out in 1X TBE for two hours, and the solution in the dialysis tube was recovered and applied to an Elutip-d column to absorb DNA to the column. After washing the column, the DNA was eluted, by increasing a concentration of an eluent, and recovered. The DNA was precipitated with ethanol, and the precipitate was dried for three minutes and dissolved in 20 μ l of distilled water. To this solution, were added 380 μ l of 1M Tris-HCl (pH 8.0) and 4 μ l of BAP C-75 enzyme solution (1/10 dilution), and a reaction was carried out for one hour at 65°C. This reaction mixture was extracted with 300 μ l each of phenol and chloroform, and washed with 600 μ l of ether.

35 E. coli JM103 containing plasmid pCTM4 was cultured by a conventional procedure, and plasmid DNA was extracted from the cultured cells by a conventional

procedure. DNA was precipitated with ethanol, and the precipitate was dried for three minutes and dissolved in 400 μ l of distilled water. This solution was extracted with 300 μ l each of phenol and chloroform, and washed with 600 μ l of ether.

Then 100 μ l of the above-mentioned solution containing DNAs of about 1.6 kb and 1.7 kb, 50 μ l of the above-mentioned solution containing DNA of about 1.9 kb, 20 μ l (75 μ g) each of 5'-phosphorylated oligonucleotides #73 and #74:

CATGCTCCCGGGTGTGGTCTTACTCCATCAG #73

TGCAGTACGAGGGCCCAACCAGAAATGAGGTAGTC #74

10 μ g of tRNA and 50 μ l of 3M sodium phosphate were mixed, and to the mixture was added 1 ml of ethanol, and the mixture allowed to stand for 20 minutes at -80°C , and centrifuged for ten minutes at 4°C and 16000 rpm to coprecipitate the DNAs with the tRNA. After removing a supernatant, the precipitate was dried and dissolved in a mixture of 8 μ l of 30 mM MgCl_2 , 4 μ l of distilled water, and 100 mM HEPES (pH 7.5), and annealing was carried out at 65°C for 20 minutes, at 42°C for 30 minutes, at a room temperature for five minutes, and then for five minutes on ice. To this mixture were added 1 μ l of 10 mM ATP, 1 μ l of 300 mM DTT, 9 μ l of 40% PEG and 2 μ l of T4 DNA ligase solution (20 minutes), and a reaction was carried out overnight at 20°C .

Then 10 μ l of this ligation mixture was used to transform E. coli RR1 by the Hunahan method, and the transformation mixture was spread on an LB ampicillin plate, and culturing was carried out overnight at 37°C . As a result, 55 colonies developed, and among them, 9 colonies were analyzed by a rapid isolation method, and was confirmed that two colonies contains the desired plasmid. This plasmid was designated as pLTM2.

This plasmid was used to transform E. coli JM103 and X 1776 to obtain Escherichia coli JM103/pLTM2, and Escherichia coli X 1776/pLTM2.

CLAIMS

1. A fused protein comprising a polypeptide containing an antibody binding site of protein A and a polypeptide of lymphotoxin, and having biological activities of lymphotoxin and an ability to bind to an antibody.

2. A fusion protein according to claim 1, wherein the polypeptide containing an antibody binding site of protein A is linked with the polypeptide of lymphotoxin directly or via a linker peptide.

3. A fusion protein according to claim 2 having the following amino acid sequence:

Met Glu Gln Arg Ile Thr Leu lys Glu Ala
Trp Asp Gln Arg Asn Gly Phe Ile Gln Ser Leu Lys Asp Asp
Pro Ser Gln Ser Ala Asn Val Leu Gly Glu Ala Gln Lys Leu
15 Asn Asp Ser Gln Ala Pro Lys Ala Asp Ala Gln Gln Asn Asn
Phe Asn Lys Asp Gln Gln Ser Ala Phe Tyr Glu Ile Leu Asn
Met Pro Asn Leu Asn Glu Ala Gln Arg Asn Gly Phe Ile Gln
Ser Leu Lys Asp Asp Pro Ser Gln Ser Thr Asn Val Leu Gly
Glu Ala Lys Lys Leu Asn Glu Ser Gln Ala Pro Lys Ala Asp
20 Asn Asn Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
Leu Asn Met Pro Asn Leu Asn Glu Glu Gln Arg Asn Gly Phe
Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu
Leu Ser Glu Ala Lys Lys Leu Asn Glu Ser Gln Ala Pro Lys
Ala Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr
25 Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn
Gly Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala
Asn Leu Leu Ala Glu Ala lys Lys Leu Asn Asp Ala Gln Ala
Pro Lys Ala Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala
Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Thr Glu Glu Gln
30 Arg Asn Gly Phe Ile Gln Ser Leu Lys Asp Asp Pro Gly Asn
Ser Lys Gly Gly Leu Asn Met Leu Pro Ply Val Gly Leu Thr
Pro Ser Ala Ala Gln Thr Ala Arg Gln His Pro Lys Met His
Leu Ala His Ser Asn Leu Lys Pro Ala Ala His Leu Ile Gly
Asp Pro Ser Lys Gln Asn Ser Leu Leu Trp Arg Ala Asn Thr
35 Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser Leu Ser Asn Asn
Ser Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val Tyr Ser

Gln Val Val Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Thr
 Ser Ser Pro Leu Tyr Leu Ala His Glu Val Gln Leu Phe Ser
 Ser Gln Tyr Pro Phe His Val Pro Leu Leu Ser Ser Gln Lys
 Met Val Tyr Pro Gly Leu Gln Glu Pro Trp Leu His Ser Met
 5 Tyr His Gly Ala Ala Phe Gln Leu Thr Gln Gly Asp Gln Leu
 Ser Thr His Thr Asp Gly Ile Pro His Leu Val Leu Ser Pro
 Ser Thr Val Phe Phe Gly Ala Phe Ala Leu.

4. DNA coding for a fused protein comprising a
 polypeptide containing an antibody binding site of
 10 protein A and a polypeptide of lymphotoxin, and having
 biological activities of lymphotoxin and an ability to
 bind to an antibody.

5. DNA according to claim 4, having the following
 nucleic acid sequence:

15 ATG GAA CAA CGC ATA ACC CTG AAA GAA GCT
 TGG GAT CAA CGC AAT GGT TTT TAC CAA AGC CTT AAA GAT GAT
 CCA AGC CAA AGT GCT AAC GTT TTA GGT GAA GCT CAA AAA CTT
 AAT GAC TCT CAA GCT CCA AAA GCT GAT GCG CAA CAA AAT AAC
 TTC AAC AAA GAT CAA CAA AGC GCC TTC TAT GAA ATC TTG AAC
 20 ATG CCT AAC TTA AAC GAA GCG CAA CGT AAC GGC TTC ATT CAA
 AGT CTT AAA GAC GAC CCA AGC CAA AGC ACT AAC GTT TTA GGT
 GAA GCT AAA AAA TTA AAC GAA TCT CAA GCT CCG AAA GCT GAT
 AAC AAT TTC AAC AAA GAA CAA CAA AAT GCT TTC TAT GAA ATC
 TTG AAT ATG CCT AAC TTA AAC GAA GAA CAA CGC AAT GGT TTC
 25 ATC CAA AGC TTA AAA GAT GAC CCA AGC CAA AGT GCT AAC CTA
 TTG TCA GAA GCT AAA AAG TTA AAT GAA TCT CAA GCA CCG AAA
 GCG GAT AAC AAA TTC AAC AAA GAA CAA CAA AAT GCT TTC TAT
 GAA ATC TTA CAT TTA CCT AAC TTA AAC GAA GAA CAA CGC AAT
 GGT TTC ATC CAA AGC CTA AAA GAT GAC CCA AGC CAA AGC GCT
 30 AAC CTT TTA GCA GAA GCT AAA AAG CTA AAT GAT GCT CAA GCA
 CCA AAA GCT GAC AAC AAA TTC AAC AAA GAA CAA CAA AAT GCT
 TTC TAT GAA ATT TTA CAT TTA CCT AAC TTA ACT GAA GAA CAA
 CGT AAC GGC TTC ATC CAA AGC CTT AAA GAC GAT CCG GGG AAT
 TCA AAA GGA GGT TTA AAT ATG CTC CCG GGT GTT GGT CTT ACT
 35 CCA TCA GCT GCC CAG ACT GCC CGT CAG CAC CCC AAG ATG CAT
 CTT GCC CAC AGC AAC CTC AAA CCT GCT GCT CAC CTC ATT GGA
 GAC CCC AGC AAG CAG AAC TCA CTG CTC TGG AGA GCA AAC ACG

GAC CGT GCC TTC CTC CAG GAT GGT TTC TCC TTG AGC AAC AAT
TCT CTC CTG GTC CCC ACC AGT GGC ATC TAC TTC GTC TAC TCC
CAG GTG GTC TTC TCT GGG AAA GCC TAC TCT CCC AAG GCC ACC
TCC TCC CCA CTC TAC CTG GCC CAT GAG GTC CAG CTC TTC TCC
5 TCC CAG TAC CCC TTC CAT GTG CCT CTC CTC AGC TCC CAG AAG
ATG GTG TAT CCA GGG CTG CAG GAA CCC TGG CTG CAC TCG ATG
TAC CAC GGG GCT GCG TTC CAG CTC ACC CAG GGA GAC CAG CTA
TCC ACC CAC ACA GAT GGC ATC CCC CAC CTA GTC CTC AGC CCT
AGT ACT GTC TTC TTT GGA GCC TTC GCT CTG.

10 6. A plasmid comprising DNA coding for a fused
protein comprising a polypeptide containing an antibody
binding site of protein A and a polypeptide of lympho-
toxin, and having biological activities of lymphotoxin
and an ability to bind to an antibody.

15 7. A plasmid according to claim 6, wherein the
plasmid is designated as pPRALT1.

8. Escherichia coli transformed with a plasmid
comprising a DNA coding for a fused protein comprising a
polypeptide containing an antibody binding site of
20 protein A and a polypeptide of lymphotoxin, and having
biological activities of lymphotoxin and an ability to
bind to an antibody.

9. A process for production of a fused protein
comprising a polypeptide containing an antibody binding
25 site of protein A and a polypeptide of lymphotoxin, and
having biological activities of lymphotoxin and an
ability to bind to an antibody, characterized by
culturing E. coli transformed with a plasmid comprising
DNA coding for said protein, and obtaining said protein
30 from the culture product.

Fig. 1




Fig. 2




Fig. 3-1

10 20 30 40 50 60
 ATG CTC CCG GGT GGT CTT ACT CCA TCA GCT GCC CAG ACT GCC CGT CAG CAC CCC AAG
 Met Leu Pro Gly Val Gly Leu Thr Pro Ser Ala Ala Gln Thr Ala Arg Gln His Pro Lys
 0 1
 70 80 90 100 110 120
 ATG CAT CTT GCC CAC AGC AAC CTC AAA CCT GCT GCT CAC CTC ATT GGA GAC CCC AGC AAG
 Met His Leu Ala His Ser Asn Leu Lys Pro Ala Ala His Leu Ile Gly Asp Pro Ser Lys
 20 30 40 50 60
 CAG AAC TCA CTG CTC TGG AGA GCA AAC ACC GAC CGT GCC TTC CTC CAG GAT GGT TTC TCC
 Gln Asn Ser Leu Leu Trp Arg Ala Asn Thr Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser
 130 140 150 160 170 180
 TTG AGC AAC AAT TCT CTC CTG GTC CCC ACC AGT GGC ATC TAC TTC GTC TAC TCC CAG GTG
 Leu Ser Asn Asn Ser Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val Tyr Ser Gln Val
 190 200 210 220 230 240
 GTC TTC TCT GGG AAA GCC TAC TCT CCC AAG GCC ACC TCC TCC CCA CTC TAC CTG GCC CAT
 Val Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Thr Ser Ser Pro Leu Tyr Leu Ala His
 250 260 270 280 290 300

 $\frac{\omega}{9}$

$$\frac{4}{9}$$

Fig. 3-2

310	GAG GTC CAG CTC TTC TCC TCC CAG TAC CCC	330	TTC CAT GTG CCT CTC CTC	350	AGC TCC CAG AAG	360
100	Glu Val Gln Leu Phe Ser Ser Gln Tyr Pro	110	Phe His Val Pro Leu Ser Ser Gln Lys			
370	ATG GTG TAT CCA GGG CTG CAG GAA CCC TGG	390	CTG CAC TCG ATG TAC CAC GGG GCT GCG TTC	420		
120	Met Val Tyr Pro Gly Leu Gln Glu Pro Trp	130	Leu His Ser Met Tyr His Gly Ala Ala Phe			
430	CAG CTC ACC CAG GGA GAC CAG CTA TCC ACC	450	CAC ACA GAT GGC ATC CCC CAC CTA GTC CTC	480		
140	Gln Leu Thr Gln Gly Asp Gln Leu Ser Thr	150	His Thr Asp Gly Ile Pro His Leu Val Leu			
490	AGC CCT AGT ACT GTC TTC TTT GGA GCC TTC	510	GCT CTG			
160	Ser Pro Ser Thr Val Phe Phe Gly Ala Phe	170	Ala Leu			

Fig. 4-2

AAT GGT TTC ATC CAA AGC TTA AAA GAT GAC CCA AGC CAA AGT GCT AAC CTA TTG TCA GAA Asn Gly Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ser Glu	466 153
GCT AAA AAG TTA AAT GAA TCT CAA GCA CCG AAA GCG GAT AAC AAA TTC AAC AAA GAA CAA Ala Lys Lys Leu Asn Glu Ser Gln Ala Pro Lys Ala Asp Asn Lys Phe Asn Lys Glu Gln	526 173
CAA AAT GCT TTC TAT GAA ATC TTA CAT TTA CCT AAC TTA AAC GAA CAA CGC AAT GGT Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Gly	586 193
TTC ATC CAA AGC CTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys	646 213
AAG CTA AAT GAT GCT CAA GCA CCA AAA GCT GAC AAC AAA TTC AAC AAA GAA CAA CAA AAT Lys Leu Asn Asp Ala Gln Ala Pro Lys Ala Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn	706 233
GCT TTC TAT GAA ATT TTA CAT TTA CCT AAC TTA ACT GAA GAA CAA CGT AAC GGC TTC ATC Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Thr Glu Glu Aln Arg Asn Gly Phe Ile	766 253
CAA AGC CTT AAA GAC GAT CCG GGG AAT TCC CGG GGA TCC GTC GAC CTG CAG Gln Ser Leu Lys Asp Asp Pro Gly Asn Ser Arg Gly Ser Val Asp Leu Gln	817 270

Linker Region

Ligation Site

$$\frac{\sigma}{\rho}$$

BNSDOCID: <EP 0317641A1 | >

CTAAGGAGGTTGT	ATG	GAA	CAA	CGC	ATA	ACC	CTG	AAA	GAA	GCT	TGG	GAT	CAA	46
Met	Glu	Gln	Arg	Ile	Thr	Leu	Lys	Glu	Ala	Trp	Asp	Gln	13	
CGC	AAT	GGT	TTT	ATC	CAA	AGC	CTT	AAA	GAT	GAT	CCA	AGC	CAA	106
Arg	Asn	Gly	Phe	Ile	Gln	Ser	Leu	Lys	Asp	Pro	Ser	Gln	Ser	33
GAA	GCT	CAA	AAA	CTT	AAT	GAC	TCT	CAA	GCT	GAT	CGC	CAA	CAA	166
Glu	Ala	Gln	Lys	Leu	Asn	Asp	Ser	Gln	Ala	Pro	Lys	Ala	Asp	53
AAC	AAA	GAT	CAA	AGC	GCC	TTC	TAT	GAA	ATC	TTG	AAC	ATG	CCT	226
Asn	Lys	Asp	Gln	Ser	Ala	Phe	Tyr	Glu	Ile	Leu	Asn	Met	Pro	73
CAA	CGT	AAC	GGC	TTC	ATT	CAA	AGT	CTT	AAA	GAC	GAC	CCA	AGC	286
Gln	Arg	Asn	Gly	Phe	Ile	Gln	Ser	Leu	Lys	Asp	Pro	Ser	Gln	93
GGT	GAA	GCT	AAA	AAA	TTA	AAC	GAA	TCT	CAA	GCA	CCG	AAA	GCT	346
Gly	Glu	Ala	Lys	Lys	Leu	Asn	Glu	Ser	Gln	Ala	Pro	Lys	Ala	113
GAA	CAA	CAA	AAT	GCT	TTC	TAT	GAA	ATC	TTG	AAT	ATG	CCT	AAC	406
Glu	Gln	Gln	Asn	Ala	Phe	Tyr	Glu	Ile	Leu	Asn	Met	Pro	Asn	133

Fig. 6




Fig. 7

(261)
 Asp Pro Gly
 GAT CCG GGG
 CTA GGC CCG TTA A
EcoRI

Sequence in Protein A-Coding Plasmid

(262)
 Asn Ser Arg Gly Ser Val ---
 AAT TCC CCG GGA TCC GTC ---
 GG GGC CCT AGG CAG ---

Asn Ser Lys Gly Gly Leu Asn Met Leu Pro Gly Val Gly Leu Thr ---
 AAT TCA AAA GGA GGT TTA AAT ATG CTC CCG GGT GTT GGT CTT ACT ---
GT TTT OCT CCA AAT TTA TAC GAG GGC CCA CAA CCA GAA TGA ---
EcoRI Sequence in Lymphotoxin-coding
 Plasmid

Asp Pro Gly Asn Ser Lys Gly Gly Leu Asn Met Leu Pro Gly Val Gly Leu Thr ---
 GAT CCG GGG AAT TCA AAA GGA GGT TTA AAT ATG CTC CCG GGT GTT GGT CTT ACT ---
 CTA GGC CCG TTA AGT TTT OCT CCA AAT TTA TAC GAG GGC CCA CAA CCA GAA TGA ---
EcoRI Sequence in Fused Protein-Coding
 Plasmid

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP89/03152641

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl ⁴ C07K13/00, 15/12, C12P21/02, C12N1/20, 15/00, A61K37/02, 39/085// (C12P21/02, C12R1:19)														
II. FIELDS SEARCHED Minimum Documentation Searched * <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; text-align: center;">IPC</td> <td style="border: none;">C07K13/00, 15/12, C12P21/02, C12N1/20, 15/00, A61K37/02, 39/085</td> </tr> </table> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched * 			Classification System	Classification Symbols	IPC	C07K13/00, 15/12, C12P21/02, C12N1/20, 15/00, A61K37/02, 39/085								
Classification System	Classification Symbols													
IPC	C07K13/00, 15/12, C12P21/02, C12N1/20, 15/00, A61K37/02, 39/085													
III. DOCUMENTS CONSIDERED TO BE RELEVANT * <table style="width: 100%; border: none;"> <tr> <th style="width: 10%; border: none;">Category *</th> <th style="width: 70%; border: none;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border: none;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: none; text-align: center;">A</td> <td style="border: none;">JP, A, 60-500480 (Pharmacia A.B.) 11 April 1985 (11. 04. 85) & WO, A, 84/03103</td> <td style="border: none; text-align: center;">1-9</td> </tr> <tr> <td style="border: none; text-align: center;">A</td> <td style="border: none;">JP, A, 61-502304 (Murphy John R.) 16 October 1986 (16. 10. 86) & WO, A, 86/00090</td> <td style="border: none; text-align: center;">1-9</td> </tr> <tr> <td style="border: none; text-align: center;">P, A</td> <td style="border: none;">JP, A, 62-190087 (Kabigen A.B.) 20 August 1987 (20. 08. 87) & EP, A, 230869</td> <td style="border: none; text-align: center;">1-9</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	JP, A, 60-500480 (Pharmacia A.B.) 11 April 1985 (11. 04. 85) & WO, A, 84/03103	1-9	A	JP, A, 61-502304 (Murphy John R.) 16 October 1986 (16. 10. 86) & WO, A, 86/00090	1-9	P, A	JP, A, 62-190087 (Kabigen A.B.) 20 August 1987 (20. 08. 87) & EP, A, 230869	1-9
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
A	JP, A, 60-500480 (Pharmacia A.B.) 11 April 1985 (11. 04. 85) & WO, A, 84/03103	1-9												
A	JP, A, 61-502304 (Murphy John R.) 16 October 1986 (16. 10. 86) & WO, A, 86/00090	1-9												
P, A	JP, A, 62-190087 (Kabigen A.B.) 20 August 1987 (20. 08. 87) & EP, A, 230869	1-9												
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> * Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family										
* Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family													
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border: none;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: none;">August 16, 1988 (16. 08. 88)</td> <td style="border: none;">August 29, 1988 (29. 08. 88)</td> </tr> <tr> <td style="border: none;">International Searching Authority</td> <td style="border: none;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: none;">Japanese Patent Office</td> <td style="border: none;"></td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	August 16, 1988 (16. 08. 88)	August 29, 1988 (29. 08. 88)	International Searching Authority	Signature of Authorized Officer	Japanese Patent Office					
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
August 16, 1988 (16. 08. 88)	August 29, 1988 (29. 08. 88)													
International Searching Authority	Signature of Authorized Officer													
Japanese Patent Office														